PCSK9 Forum
Click here to forward this email to a colleague
Facebook Twitter RSS YouTube linkedin
Home  |  About  |  PCSK9  |  News  |  Commentary  |  Trials  |  Videos  |  Resources  |  Contact
2017 Updated European Clinical Guidance for Use of a PCSK9 inhibitor

Following publication of the first outcomes studies with PCSK9 inhibitors, clinicians have been asking for new practical guidance for their use in the clinic. This Joint Task Force from the European Society of Cardiology and European Atherosclerosis Society addresses this need. The focus is on patients with clinical atherosclerotic cardiovascular disease, as well as primary prevention patients with familial hypercholesterolaemia (FH, inherited high cholesterol) with substantial LDL cholesterol burden.

New to this guideline:
  • Three defined LDL cholesterol thresholds (levels) to consider a PCSK9 inhibitor
  • Practical clinical algorithms
  • Emphasis on the role of imaging in risk assessment
  • Practical advice on monitoring response to LDL-lowering therapies
Prof. Ulf Landmesser (Charité Universitätsmedizin Berlin, Germany) lead author from the European Society of Cardiology, discusses key points of the guidance here.
Intracellular actions of PCSK9

Read the report here »

More News from the 7th PCSK9 Forum Expert Meeting, Barcelona, Spain

How Do We Identify Very High Risk Patients for PCSK9 Inhibition?

 
Prof. Erik Stroes (Academic Medical Center, Amsterdam, the Netherlands) makes the case for simple approaches to clinical profiling

Watch the presentation »

Prof. Ulf Landmesser discusses the role of imaging

Watch the presentation »


Profiling Patients with ACS: What are the prospects for PCSK9 Inhibition?

A pertinent question with ODYSSEY Outcomes expected early in 2018. Prof. Gregory G. Schwartz (VA Medical Center, Denver, USA) discusses.

Watch the presentation »
Check back for the latest news and views about PCSK9 science and translation to the clinic
Like us on Facebook
For the latest updates, PCSK9 news and analysis.
Follow us on Twitter
Hot topics, news and conference reports.
YouTube Channel
For videos, interviews and webcasts from leading experts.
Our popular therapeutic guide

Read online & download second edition now »

Register now at www.pcsk9forum.org to receive the updated third edition e-book with post ACC17 content including the FOURIER trial.
New eBook
Questions & Answers

Why are new treatments needed?


Read the full answer and other questions on the PCSK9 Forum »
Educational Partners
and Supporters
Amgen The Medicines Company pFizer Sanofi
Copyright PCSK9 Forum 2017. Please click here to unsubscribe from future mailings.
‚Äč